ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-22	NT$16.05	+0.63%	57,451
26-10-21	NT$15.95	-0.93%	14,304
26-10-20	NT$16.10	-1.23%	26,316
26-10-19	NT$16.30	-0.31%	54,499

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-22			5-day change	1st Jan Change
16.05 ^TWD	+0.63%		-1.83%	-22.09%

Oct. 15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
Aug. 12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	1.16B 35.52M 31.76M 29.38M 26.61M 49.8M 3.38B 50.61M 354M 140M 1.77B 133M 130M 5.6B	P/E 2024	-11.3x	P/E 2025	-9.04x
Enterprise Value	1.1B 33.84M 30.26M 28M 25.35M 47.45M 3.22B 48.22M 337M 133M 1.68B 127M 124M 5.33B	EV / Sales 2024	35.4x	EV / Sales 2025	29.7x
Free-Float	28.72%	Yield 2024 *	-	Yield 2025	-

Oct. 15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
Aug. 12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Apr. 08	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-13	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-17	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-13	Enimmune corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-03-13	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-08-11	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-21	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-08-15	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-04-26	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-08-13	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	CI
21-04-22	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	CI

1 day	+0.63%
1 week	-1.83%
Current month	-0.62%
1 month	-3.31%
3 months	-3.60%
6 months	-17.48%
Current year	-22.09%

Enimmune corporation Stock

Stocks

6564

TW0006564008

Biotechnology & Medical Research

Valuation: Enimmune corporation

Chart: Enimmune corporation

Latest news: Enimmune corporation

Quotes and Performance

Price Extremes

Managers and Directors: Enimmune corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	15.65	16.35
1 month	15.4	17.05
Current year	14.9	22.15
1 year	14.9	22.65
3 years	14.65	49.3
5 years	14.65	75.3
10 years	14.49	125

Manager	Title	Age	Since
Che Wei Chang CEO	Chief Executive Officer	-	2019-01-06
Ching Fen Yang CTO	Chief Tech/Sci/R&D Officer	-	2014-07-20
Hung Tun Chen AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Chung Cheng Liu CHM	Chairman	-	2019-01-06
Fei Pan BRD	Director/Board Member	-	2014-01-01
Chin Yi Chiu BRD	Director/Board Member	-	2015-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENIMMUNE CORPORATION	+0.63%	-1.83%	-28.67%	-56.62%	35.52M
WUXI APPTEC CO., LTD.	+0.88%	+1.18%	+40.64%	+74.91%	64.69B
ARGENX SE	-0.26%	+6.91%	+9.79%	+77.36%	54.78B
LONZA GROUP AG	+0.47%	+3.52%	+9.71%	+100.95%	53.49B
IQVIA HOLDINGS INC.	-2.08%	+2.89%	+25.82%	+48.34%	45.98B
BEONE MEDICINES AG	-1.98%	+0.07%	+17.44%	+123.36%	42.94B
REVOLUTION MEDICINES, INC.	-2.52%	+0.35%	+215.20%	+818.06%	40.08B
CELLTRION, INC.	-2.26%	-2.06%	+15.38%	+45.14%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	+0.22%	-4.77%	+26.59%	+0.55%	23.97B
GENMAB A/S	+12.10%	+16.60%	+58.50%	+46.15%	23.67B
Average	+0.52%	+1.82%	+39.04%	+127.82%	38.31B
Weighted average by Cap.	+0.00%	+2.59%	+43.80%	+149.83%

	2024	2025
Net sales	39.92M 1.22M 1.1M 1.01M 917K 1.72M 117M 1.74M 12.19M 4.82M 60.94M 4.6M 4.5M 193M	48.19M 1.48M 1.32M 1.22M 1.11M 2.07M 141M 2.11M 14.72M 5.82M 73.58M 5.55M 5.43M 233M
Net income	-158M -4.83M -4.32M -4M -3.62M -6.78M -460M -6.89M -48.12M -19.03M -241M -18.14M -17.75M -762M	-164M -5.04M -4.51M -4.17M -3.78M -7.07M -480M -7.18M -50.19M -19.86M -251M -18.92M -18.52M -794M
Net Debt	-382M -11.72M -10.48M -9.7M -8.78M -16.43M -1.12B -16.7M -117M -46.15M -583M -43.99M -43.05M -1.85B	-54.59M -1.67M -1.5M -1.39M -1.25M -2.35M -159M -2.39M -16.67M -6.6M -83.35M -6.29M -6.15M -264M